Taken together, these results suggest that the combination of anti-PD-L1 treatments and CD4+ T cell depletion may inhibit CT26 tumor growth via the activation of CD8+ T cells and the reduction of immunosuppressive PD-L1+ immune cells. Here, CD8A is linked to neoplasm.